Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 17, 2004. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
- Shareholding Increase: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan increased from 18,727,936 to 18,870,513.
- Transaction Date: The movement in the fund occurred on May 13, 2004.
- Average Price: The shares were acquired at an average price of $41.70.
Management Commentary and Risks
The filing notes that the Plan is a discretionary fund where all employees or former employees are potential beneficiaries. Consequently, two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of May 13, 2004 (18,870,513).
- Confirm the average acquisition price of $41.70 for the period.
- Note the potential indirect interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.